DEKA Medical Announces Break-through in Treating Hypopigmentation : The Excilite-u

SAN FRANCISCO, Nov. 8, 2010 /PRNewswire/ -- DEKA Medical announced today the immediate availability of the Excilite-u in the United States for the treatment of Leukoderma, Psoriasis, and Vitiligo.  The Excilite-u uses a high intensity Monochromatic Excimer Light of 308nm to stimulate melanocytes in affected areas and restore color to the skin. The system is cleared for use on all parts of the body including hard to treat areas such as hands, elbows and knees. Developed by DEKA in Italy, the system has already safely treated thousands of patients in Europe.

Leukoderma, which is a general term for lightening of the skin after an inflammatory occurrence, is often a problem for patients after laser skin resurfacing, deep chemical peels, cryotherapy, dermabrasion and other treatments. According to statistics released by the American Society of Plastic Surgery, the number of these types of treatments has skyrocketed over the last few years with more than 693,000 treatments performed in the United States alone. It has been reported that hypopigmentation can affect as many as 12% of these patients, especially those with darker colored skin.

Dr. Brian Biesman, Director of the Nashville Center for Laser and Facial Surgery in Nashville, Tennessee is leading the development of the Excilite for treatment of leukoderma arising as a result of previous laser or chemical treatments. "Although my initial work is not based on a controlled clinical study, I can say I am seeing results from the Excilite that are noticeable to myself and my patients," said Dr. Biesman. "Prior to the Excilite, patients had few options for patients seeking improvement in their hypopigmentation.  I have seen improvement in hypopigmentation caused by laser resurfacing, surgical scars, cryotherapy, deep chemical peels, and surgical scars," added Dr. Biesman.

"We are excited to bring this world-class technology to the United States and offer hope to the many patients seeking solutions to post-resurfacing hypopigmentation," commented Dale Koop, CEO of DEKA Medical. "When one also takes into account the proven ability to treat afflictions such as psoriasis and vitiligo, the Excilite-u should quickly become a prominent system in every dermatology practice."

DEKA Medical, based in San Francisco, CA is the North American Division of the El.En. Group, a worldwide leader and pioneer in the laser market and industry based near Florence, Italy. In addition to the Excilite, DEKA Medical markets the SmartXide DOT, Synchro HP, PhotoSilk, MiniSilk and Excilite lasers for aesthetic treatments such as wrinkle reduction, vein erasure, hair removal, photorejuvenation, and skin tightening. www.dekamedinc.com

SOURCE DEKA Medical